Market Overview - The A-share market continues to exhibit a narrow fluctuation pattern, with the PEEK materials concept sector experiencing a significant surge, with intraday gains exceeding 8% [1][4][8] - The overall performance of the A-share market remains stable, with major indices showing low volatility levels for the year [4] Sector Performance - The daily chemical sector saw a substantial increase, with intraday gains approaching 3%, featuring stocks like Marubi Biotechnology and Shanghai Jahwa among the top performers [5] - The home furnishing sector also rose significantly, with intraday gains exceeding 2%, highlighted by Gujia Home's stock hitting the daily limit [6] - Other sectors such as advertising packaging, electrical instruments, public transportation, and industrial machinery also reported notable gains [7] Futures Market - The futures market displayed a relatively calm performance overall, although the shipping futures continued to plummet, with the European shipping index main futures experiencing an intraday drop of over 9% [2][16] - Since April, the European shipping index main futures have been on a downward trend, accumulating a decline of over 40% due to international circumstances and supply-demand dynamics [3][17] Individual Stock Movements - Individual stock performance has shown divergence, with some stocks experiencing consecutive daily limit increases, such as Hongbo Co. and Yuzhong Sanxia A, both hitting the daily limit for three consecutive trading days [10][11] - Conversely, ST Saiwei has faced a continuous decline, hitting the daily limit down for three consecutive trading days, with warnings regarding its financial stability [12] Hong Kong Market - The Hong Kong market performed relatively well, with the Hang Seng Index and the Hang Seng Tech Index showing intraday gains of over 1% and 2% respectively [14] - The pharmaceutical sector in Hong Kong saw significant gains, with companies like Alibaba Health and WuXi AppTec among the top performers [15]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a 28.6% year-on-year increase in non-net profit attributable to the parent company for Q1 2025, indicating sustained upward momentum [4] - The company's revenue for 2024 reached 2.97 billion yuan, a 33.4% increase year-on-year, with a net profit of 342 million yuan, up 31.7% [4] - For Q1 2025, the company achieved revenue of 847 million yuan, a 28.0% increase, and a net profit of 135 million yuan, up 22.1% [4] - The forecast for net profit attributable to the parent company for 2025-2027 is 456 million, 597 million, and 763 million yuan respectively, with corresponding EPS of 1.14, 1.49, and 1.90 yuan [4] Financial Performance Summary - The company’s revenue and net profit growth rates for 2024 are 33.4% and 31.7% respectively, with a gross margin of 73.7% [7] - The revenue breakdown for 2024 shows significant growth in various product categories: eye care (+60.8%), skincare (+21.6%), cleansing (+8.8%), and beauty products (+40.5%) [5] - The company’s gross margin for Q1 2025 is reported at 76.1%, reflecting a 1.4 percentage point increase [5] - The company’s operating cash flow for 2023 was 338 million yuan, with a projected increase to 534 million yuan in 2025 [9] Product and Brand Performance - The company’s flagship products, such as the "Little Red Pen" and "Little Gold Needle," have shown remarkable sales performance, with the former achieving a GMV of 530 million yuan, a 146% increase [5] - The brand's user engagement is increasing, with active membership and repurchase amounts rising by 31% and 48% year-on-year respectively [6] - The company has established a strong market presence on platforms like Douyin, with a projected GMV of 1 to 1.5 billion yuan in 2024 [6]

Investment Rating - The report maintains an "Outperform" rating for the social services industry [1][27]. Core Insights - The report emphasizes the importance of expanding service consumption and highlights that new consumption continues to attract funding [1][3]. - The macroeconomic environment is supportive of service consumption growth, with government policies aimed at increasing income for low- and middle-income groups and enhancing consumption's role in economic growth [4][5]. - The report notes that service consumption has a high frequency of transactions, strong multiplier effects, and sustainable growth potential, with significant contributions to overall consumer spending [5]. Summary by Sections Macroeconomic and Industry Dynamics - The Politburo meeting on April 25 discussed the current economic situation, emphasizing support for technology innovation, consumption expansion, and stable foreign trade [3][4]. - The State Taxation Administration revised the management measures for tax refunds for overseas travelers, facilitating easier tax refund processes [4]. - Recent reports highlight the importance of service consumption as a key driver for domestic demand, with a projected 6.2% growth in service retail sales in 2024, outpacing goods retail sales [5]. Company Dynamics - Traditional retail continues to optimize, with companies like Yonghui Supermarket successfully launching products through green channels for foreign trade [6][7]. - Beauty industry companies reported strong financial performances, with Jinbo Bio achieving a 62.51% year-on-year revenue increase in Q1 2025 [3][13]. - The report highlights the performance of various companies, including a significant turnaround for Bubugao, which reported a 164.16% increase in net profit in 2024 [7][14]. Investment Recommendations - The report notes that the social services sector has seen a rotation in performance, with key companies trading at a PE ratio of 20-40 times for 2025, indicating stable operations and solid growth potential [3][27]. - The report suggests that the market is favoring high-growth companies within the social services sector, with significant year-to-date increases in stock prices for companies like Shangmei and Maogeping [24][27].

Core Viewpoint - The company reported strong financial performance for 2024 and Q1 2025, with significant year-on-year growth in revenue and net profit, indicating robust operational momentum and brand strength [1][6]. Financial Performance - In 2024, the company achieved revenue of 2.97 billion yuan, a year-on-year increase of 33.4%, and a net profit attributable to shareholders of 340 million yuan, up 31.7% [1][2]. - For Q1 2025, the company reported revenue of 850 million yuan, reflecting a 28% year-on-year growth, and a net profit of 140 million yuan, which is a 22.1% increase [2][6]. - The company proposed a cash dividend of 0.5 yuan per share for 2024, resulting in a total payout ratio of 88% for the year [1]. Brand and Product Performance - The main brands, Marubi and Lianhuo, experienced substantial growth, with Marubi's revenue reaching 2.055 billion yuan (69% of total revenue) and a growth of 31.7%, while Lianhuo's revenue was 905 million yuan (30% of total revenue) with a growth of 40.7% [3]. - Key product categories such as eye care, skincare, cleansing, and beauty products saw significant revenue contributions, with eye care growing by 60.8% and skincare by 21.6% in 2024 [3][4]. Gross Margin and Cost Control - The gross margin for 2024 improved by 3.0 percentage points to 73.7%, driven by product mix optimization and cost control [4][5]. - The company maintained a good control over expenses, with the expense ratio decreasing by 0.2 percentage points to 60.7% in 2024 [5]. Inventory and Receivables Management - Inventory at the end of 2024 increased by 27.9% to 220 million yuan, with inventory turnover days of 90 days [5]. - Accounts receivable rose by 42.9% to 450,000 yuan at the end of 2024, with turnover days of 4 days [5]. Future Outlook - The company is expected to continue its strong growth trajectory, with projected net profits of 450 million yuan, 570 million yuan, and 680 million yuan for 2025, 2026, and 2027, respectively [6]. - The company’s strategic focus on product innovation and brand strength is anticipated to enhance its market position and profitability [6].

Summary of the Conference Call for Perfect Diary (完美生物技术股份有限公司) Company Overview - The conference call discusses the financial performance and strategic initiatives of Perfect Diary, a leading player in the beauty and skincare industry, particularly focusing on its transformation and growth in the market. Key Financial Performance - **Q1 2025 Revenue**: 847 million yuan, a year-on-year increase of 28%, marking nine consecutive quarters of revenue and profit growth [2][4] - **2024 Revenue**: 2.97 billion yuan, a year-on-year increase of 33.44%, with main business revenue accounting for 99.94% [4] - **Gross Margin**: 2024 gross margin at 73.7%, up 3.01 percentage points year-on-year; Q1 2025 gross margin at 76.05%, up 1.45 percentage points year-on-year [2][5] - **Net Profit**: 2024 net profit attributable to shareholders at 342 million yuan, up 31.69% year-on-year; Q1 2025 net profit at 135 million yuan, up 22.07% year-on-year [2][5] Brand Performance - **Perfect Brand Revenue**: 2 billion yuan in 2024, accounting for 69% of total revenue, with eye products contributing 33% [6] - **PL Brand Revenue**: 900 million yuan in 2024, accounting for 30% of total revenue, with foundation products achieving over 100 million yuan in GMV [6] - **Online vs. Offline Growth**: Online channel revenue grew by 36% while offline grew by 21%, indicating a stronger performance in online sales [6] Research and Development - **R&D Investment**: 73.5 million yuan in 2024, an 18% increase year-on-year; a total of 596 patents applied, with 319 granted [8] - **Industry Leadership**: The company leads in R&D and patent reserves, having published 53 papers and participated in 82 standard-setting initiatives [8] Marketing and Brand Strategy - **Marketing Shift**: Transitioned from "eye care expert" to "focusing on reducing fine lines," emphasizing user connection and brand value [4][11] - **Product Strategy**: Focus on big product strategies, with significant upgrades to key products like the small red pen eye cream [12][16] - **Social Media Marketing**: Achieved significant engagement through short videos, with 1.2 billion views and high new customer conversion rates [19][25] Sustainability and Corporate Governance - **Sustainability Initiatives**: Selected as a green factory in Guangdong, with multiple products achieving carbon neutrality certifications [10] - **Dividend Policy**: Consistent dividends since 2019, totaling 900 million yuan, reflecting a commitment to shareholder returns [9] Future Outlook - **Growth Strategy**: Plans to enhance technology innovation and operational efficiency, aiming to solidify its position as a leading company in the industry [14][51] - **Product Expansion**: Introduction of new products like the collagen small gold needle and the whitening essence, with sales targets set for significant growth [52] Challenges and Responses - **Market Competition**: Acknowledgment of fierce competition in the sunscreen market, with a focus on anti-aging products [55] - **Channel Strategy**: Addressing challenges in offline sales by enhancing customer experience and maintaining a robust online presence [27][46] Conclusion - Perfect Diary demonstrates strong financial performance, innovative marketing strategies, and a commitment to sustainability, positioning itself for continued growth in the competitive beauty industry. The company is focused on leveraging technology and enhancing customer engagement to drive future success.

Investment Rating - The report maintains a "Recommendation" rating for the consumer discretionary sector [5] Core Insights - The beauty and personal care segment shows strong growth, with companies like Proya achieving over 10 billion RMB in revenue for the first time, and significant increases in net profit [3][26] - The retail sector is expanding, with ALDI opening new stores and achieving record sales, while companies like Yonghui Supermarket are recovering from previous losses [25][34] - The travel and leisure industry is also seeing growth, with increased flight operations and significant revenue increases for companies like Xiangyuan Culture [21][34] Summary by Sections Market Performance - For the week of April 21-25, 2025, the Shenyin Wanguo indices for retail, social services, and beauty care sectors showed mixed performance, with beauty care up by 3.80% [10][12] - The beauty care sub-sector outperformed others, with individual products and cosmetics increasing by 7.11% and 4.89% respectively [11] Key Industry Data and News - Proya's revenue for 2024 reached 10.778 billion RMB, marking a 21% increase, while its net profit rose by 30% [3][26] - Other companies like Marubi and Betaini also reported significant revenue growth, with Marubi's revenue increasing by 33.4% in 2024 [3][29] - The travel sector saw a rise in flight operations, with nearly 106,000 flights executed in the week of April 14-20, 2025, reflecting an 8.7% increase year-on-year [21][23] Key Company Announcements - Proya's Q1 2025 revenue was 2.359 billion RMB, a year-on-year increase of 8.13% [26] - Marubi reported a Q1 2025 revenue of 847 million RMB, up 28.01% from the previous year [29] - Bubble Mart's Q1 2025 revenue surged by 165%-170%, with overseas revenue increasing by over 475% [33]

Core Viewpoint - Domestic beauty brands are gaining competitive advantages in the market through high cost-performance ratios and refined operations [1][7]. Group 1: Market Performance - In early 2024, the retail sales of cosmetics in China are projected to be 435.7 billion yuan, a year-on-year decline of 1.1% [2]. - Despite the overall market stagnation, several domestic beauty companies have reported impressive performance, with Proya (603605.SH) achieving a revenue of 10.778 billion yuan, a year-on-year increase of 21.04% [2][3]. - Other established beauty companies such as Shiseido (02145.HK), Maogeping (01318.HK), and Marubi (603983.SH) also reported revenue growth exceeding 20% [2]. Group 2: Online Sales Strategy - Leading beauty companies are increasingly focusing on online sales, with Proya's online sales ratio exceeding 95% and sales surpassing 10 billion yuan [4]. - Shiseido's online sales ratio is over 90%, with sales exceeding 6 billion yuan, while Marubi's online sales ratio is above 85% [4]. - In the e-commerce landscape, Douyin has emerged as a significant player, with total beauty sales reaching between 2.5 billion to 5 billion units and total sales exceeding 100 billion yuan [4]. Group 3: Quarterly Performance - In Q1 2025, the retail sales of cosmetics reached 114.9 billion yuan, a year-on-year increase of 3.2% [6]. - Proya reported a Q1 2025 revenue of 2.359 billion yuan, up 8.13% year-on-year, and a net profit of 390 million yuan, up 28.87% [6]. - Marubi achieved a Q1 2025 revenue of 847 million yuan, a year-on-year increase of 28.01%, with a net profit of 135 million yuan, up 22.07% [6]. Group 4: Future Outlook - The management of Juzhi Biological aims for a revenue growth of 25% to 28% and a net profit growth of 21% to 24% for the 2025 fiscal year [7]. - The cosmetics and medical beauty industry is expected to show stable growth driven by policy support and consumer recovery [7]. - Domestic beauty brands are focusing on reducing traffic costs and enhancing digital marketing strategies to ensure measurable business growth [7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.01 CNY [3][8]. Core Insights - The company is expected to achieve strong performance in 2025, with projected earnings per share (EPS) of 1.11 CNY, 1.44 CNY, and 1.85 CNY for the years 2025, 2026, and 2027 respectively [2][8]. - The company reported a revenue of 2.97 billion CNY in 2024, reflecting a year-on-year growth of 33.4%, and a net profit attributable to the parent company of 342 million CNY, up 31.7% year-on-year [7]. - The online channel transformation has shown positive results, with online revenue reaching 2.54 billion CNY in 2024, accounting for 86% of total revenue, and growing by 35.8% year-on-year [7]. Financial Performance Summary - Revenue projections for 2025-2027 are as follows: 3.78 billion CNY in 2025, 4.67 billion CNY in 2026, and 5.66 billion CNY in 2027, with respective growth rates of 27.2%, 23.6%, and 21.3% [2][11]. - The company's gross margin is expected to improve to 74.8% in 2025, with a net profit margin of 11.8% [2][11]. - The return on equity (ROE) is projected to increase to 12.4% in 2025 and further to 16.4% by 2027 [2][11]. Brand and Product Performance - The main brand, Marubi, achieved a revenue of 2.06 billion CNY in 2024, growing by 31.69%, while the PL brand, Lianhuo, saw a revenue increase of 40.72% to 905 million CNY [7]. - Revenue growth rates for product categories in 2024 were as follows: eye care at 61%, skincare at 22%, cleansing at 9%, and makeup at 40% [7]. Market Position and Strategy - The company has successfully transitioned from a traditional cosmetics firm to a biotechnology beauty company, as indicated by its rebranding to "Marubi Biotechnology" [7]. - The company is focusing on optimizing product structure and cost control, which has contributed to the improvement in gross margins [7].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][16][20] Core Views - The company achieved a revenue of 2.97 billion in 2024, representing a year-on-year growth of 33.44%, with a net profit attributable to the parent company of 342 million, up 31.69% year-on-year [1][7] - The main brand, Marubi, generated a revenue of 2.055 billion in 2024, reflecting a growth of 31.69%, while the secondary brand, Lianhuo, achieved a revenue of 905 million, up 40.72% [2][8] - The company is experiencing a product momentum explosion, particularly with its key products, which are driving significant revenue and profit growth [3][16] Financial Performance - In Q1 2025, the company reported a revenue of 847 million, a year-on-year increase of 28.01%, and a net profit of 135 million, up 22.07% [1][7] - The gross margin for 2024 was 73.70%, an increase of 3.01 percentage points year-on-year, and is projected to rise to 76.05% in Q1 2025 [3][11] - The company’s operating cash flow for 2024 was 301 million, showing a decrease of 11.09% year-on-year, while Q1 2025 saw a significant increase of 117.93% [14] Revenue Breakdown - The eye care category generated 689 million in revenue for 2024, a growth of 60.78%, primarily driven by the Marubi Xiaohong Pen eye cream [2][8] - Online sales channels contributed 2.541 billion in revenue for 2024, up 35.77%, accounting for 85.55% of total revenue [2][8] - The company’s top three core products accounted for 64% of sales, indicating a further increase in product concentration [2][8] Profitability Metrics - The net profit margin for 2024 was 11.53%, a decrease of 0.94 percentage points year-on-year, while the gross profit margin continued to improve [11][18] - The company’s return on equity (ROE) is projected to reach 10.1% in 2024, increasing to 17.4% by 2027 [4][18] Future Projections - The company is expected to achieve a revenue of 3.941 billion in 2025, with a net profit of 476 million, reflecting a growth of 32.7% and 39.4% respectively [4][18] - The forecast for 2027 includes a net profit of 822 million, with a corresponding price-to-earnings (PE) ratio of 20x [3][4][16]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.01 CNY [3][8] Core Insights - The company is expected to achieve strong performance in 2025, with projected earnings per share (EPS) of 1.11 CNY, 1.44 CNY, and 1.85 CNY for the years 2025, 2026, and 2027 respectively [2][8] - The company reported a revenue of 2.97 billion CNY in 2024, reflecting a year-on-year growth of 33.4%, and a net profit attributable to the parent company of 342 million CNY, up 31.7% year-on-year [7] - The online channel transformation has shown positive results, with online revenue reaching 2.54 billion CNY in 2024, accounting for 86% of total revenue, and growing by 35.8% year-on-year [7] Financial Performance Summary - Revenue projections for 2025-2027 are as follows: 3.78 billion CNY in 2025, 4.67 billion CNY in 2026, and 5.66 billion CNY in 2027, with respective growth rates of 27.2%, 23.6%, and 21.3% [2][11] - The gross profit margin is expected to increase to 74.8% in 2025, with a net profit margin of 11.8% [2][11] - The company’s return on equity (ROE) is projected to rise to 12.4% in 2025 and 16.4% in 2027 [2][11] Brand and Product Performance - The main brand, Marubi, achieved a revenue of 2.06 billion CNY in 2024, growing by 31.69%, while the PL brand, Lianhuo, saw a revenue increase of 40.72% to 905 million CNY [7] - Revenue growth rates for product categories in 2024 were as follows: eye care at 61%, skincare at 22%, cleansing at 9%, and makeup at 40% [7] Market Position and Strategy - The company has successfully implemented a three-year online and offline channel strategy, which has stabilized market order and pricing systems [7] - The rebranding to "Marubi Biotechnology" signifies a strategic shift from traditional beauty products to biotechnology-based beauty solutions [7]